284 related articles for article (PubMed ID: 12583828)
1. Novel antifolate drugs.
Purcell WT; Ettinger DS
Curr Oncol Rep; 2003 Mar; 5(2):114-25. PubMed ID: 12583828
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
3. Antifolates in clinical development.
Takimoto CH
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-40-S18-51. PubMed ID: 9420020
[TBL] [Abstract][Full Text] [Related]
4. The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs.
Theti DS; Jackman AL
Clin Cancer Res; 2004 Feb; 10(3):1080-9. PubMed ID: 14871988
[TBL] [Abstract][Full Text] [Related]
5. Molecular, biochemical, and cellular pharmacology of pemetrexed.
Goldman ID; Zhao R
Semin Oncol; 2002 Dec; 29(6 Suppl 18):3-17. PubMed ID: 12571805
[TBL] [Abstract][Full Text] [Related]
6. Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake.
Drori S; Jansen G; Mauritz R; Peters GJ; Assaraf YG
J Biol Chem; 2000 Oct; 275(40):30855-63. PubMed ID: 10899164
[TBL] [Abstract][Full Text] [Related]
7. Anticancer antifolates: current status and future directions.
McGuire JJ
Curr Pharm Des; 2003; 9(31):2593-613. PubMed ID: 14529544
[TBL] [Abstract][Full Text] [Related]
8. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL
Br J Cancer; 1998; 78 Suppl 3(Suppl 3):27-34. PubMed ID: 9717988
[TBL] [Abstract][Full Text] [Related]
9. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of antitumor antifolates.
Newell DR
Semin Oncol; 1999 Apr; 26(2 Suppl 6):74-81. PubMed ID: 10598559
[TBL] [Abstract][Full Text] [Related]
11. Deaza analogs of folic acid as antitumor agents.
Kisliuk RL
Curr Pharm Des; 2003; 9(31):2615-25. PubMed ID: 14529545
[TBL] [Abstract][Full Text] [Related]
12. Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL
Semin Oncol; 1999 Apr; 26(2 Suppl 6):48-54. PubMed ID: 10598555
[TBL] [Abstract][Full Text] [Related]
13. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
[TBL] [Abstract][Full Text] [Related]
14. New antifolates in clinical development.
Takimoto CH; Allegra CJ
Oncology (Williston Park); 1995 Jul; 9(7):649-56, 659 DISC 660, 662, 665. PubMed ID: 8924375
[TBL] [Abstract][Full Text] [Related]
15. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line.
Wang Y; Zhao R; Goldman ID
Biochem Pharmacol; 2003 Apr; 65(7):1163-70. PubMed ID: 12663051
[TBL] [Abstract][Full Text] [Related]
17. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
[TBL] [Abstract][Full Text] [Related]
18. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
[TBL] [Abstract][Full Text] [Related]
19. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
Assaraf YG
Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765
[TBL] [Abstract][Full Text] [Related]
20. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
Shih C; Habeck LL; Mendelsohn LG; Chen VJ; Schultz RM
Adv Enzyme Regul; 1998; 38():135-52. PubMed ID: 9762351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]